In non-small cell lung cancer, FBZ inhibited growth by increasing p53 activation, inhibiting the transporter protein GLUT1 and hexokinase, and reducing glucose uptake in cancer cells (Xu et al., 2022). This evidence concerns the gene SLC2A1 and non-small cell lung carcinoma.